ArticleCancer research2021
Genomic Alterations in
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Preclinical Anticipation of On- and Off-Target Resistance Mechanisms to Anti-Cancer Drugs: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer.Molecular cancer therapeutics · 2026Article
- Mechanisms of mTORC1 and GCN2 amino acid sensing pathways in tumorigenesis and metastatic progression (Review).International journal of molecular medicine · 2026Review
- GATOR1 complex controls cisplatin sensitivity.Cell death & disease · 2025Article
- Hif-1 responsive IFFLs to explain specific transcriptional responses to cycling hypoxia in cancers.NPJ systems biology and applications · 2025Article
- AdaSemb: an adaptive knowledge-driven deep learning framework integrating cancer protein assemblies for predicting PI3Kα inhibitor response and resistance.Briefings in bioinformatics · 2025Article
- Polo-like kinase 1 inactivation enhances PI3K inhibition-mediated apoptosis of NOTCH1-mutant head and neck squamous cell carcinoma.Cancer letters · 2025Article
- CRISPR screening approaches in breast cancer research.Cancer metastasis reviews · 2025Review
- Uncoupling of Akt and mTOR signaling drives resistance to Akt inhibition in PTEN loss prostate cancers.Science advances · 2025Article
- Article
- Research into overcoming drug resistance in lung cancer treatment using CRISPR-Cas9 technology: a narrative review.Translational lung cancer research · 2024Review
- NPRL2 is required for proliferation of oncogenic Ras-transformed bronchial epithelial cells.Cell division · 2024Article
- Role of MARK2 in the nervous system and cancer.Cancer gene therapy · 2024Review
- Impact of Extracellular Matrix-Related Genes on the Tumor Microenvironment and Prognostic Indicators in Esophageal Cancer: A Comprehensive Analytical Study.Genetics research · 2024Article
- Inhibition of phosphatidylinositol 3-kinase catalytic subunit alpha by miR-203a-3p reduces hypertrophic scar formation via phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway.Burns & trauma · 2024Article
- Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer.NPJ breast cancer · 2023Review
- Characterization of the mScientific reports · 2023Article
- Dysregulated Amino Acid Sensing Drives Colorectal Cancer Growth and Metabolic Reprogramming Leading to Chemoresistance.Gastroenterology · 2023Article
- Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements.Cancers · 2023Review
- The role of TSC2 in breast cancer: a literature review.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 4 institutions in 3 countries.
Yanyan Cai *Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, New York. maurizio.scaltriti@astrazeneca.com caiy@mskcc.org.
Guotai Xu *Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, New York.
Fan WuHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-3960-320X
Flavia MicheliniHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, New York.
Carmen ChanHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-9086-6622
Xuan QuHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, New York.
Pier SelenicaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Erik LadewigHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, New York.
Pau CastelHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.ORCID 0000-0002-4972-4347
Yuanming ChengMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Alison ZhaoHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-5479-2686
Komal JhaveriDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Eneda ToskaHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, New York.
Marta JimenezUnicancer, Paris, France.
Alexandra JacquetUnicancer, Paris, France.ORCID 0000-0001-9244-5370
Alicia Tran-DienINSERM UMR981 and Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
Fabrice AndreINSERM UMR981 and Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.ORCID 0000-0001-5795-8357
Sarat ChandarlapatyHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-4532-8053
Jorge S Reis-FilhoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Pedram RazaviHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, New York.
Maurizio ScaltritiHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, New York. maurizio.scaltriti@astrazeneca.com caiy@mskcc.org.ORCID 0000-0002-5522-1447
Memorial Sloan Kettering Cancer Center · USInserm · FRUniCancer Group · FRUCSF Helen Diller Family Comprehensive Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4MUnraveling resistance to PI3K-alpha inhibitors in breast cancerR01CA190642 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SCALTRITI, MAURIZIO · 2015 to 2019
$2.2MResistance and Evolution of Metastatic Breast CancerK00CA212478 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LADEWIG, ERIK · 2018 to 2021
$369kNCI NIH HHS K00 CA212478NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA190642
Abstract
PI3Kα inhibitors have shown clinical activity in PIK3CA-mutated estrogen receptor-positive (ER
Indexed as
Loss of Function MutationAnimalsBreast NeoplasmsCell SurvivalClass I Phosphatidylinositol 3-KinasesCohort StudiesDrug Resistance, NeoplasmFemaleHEK293 CellsHumansMCF-7 CellsMechanistic Target of Rapamycin Complex 1MicePhosphoinositide-3 Kinase InhibitorsSignal TransductionThiazolesAlpelisibClass I Phosphatidylinositol 3-KinasesMechanistic Target of Rapamycin Complex 1MTOR protein, humanPhosphoinositide-3 Kinase InhibitorsPIK3CA protein, humanThiazolesTOR Serine-Threonine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.